S0820, Adenoma and Second Primary Prevention Trial
Status:
Recruiting
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that the combination of eflornithine and sulindac will be
effective in reducing a three-year event rate of adenomas and second primary colorectal
cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Southwest Oncology Group
Collaborators:
Cancer Prevention Pharmaceuticals, Inc. National Cancer Institute (NCI)